Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.

1. Boehringer Ingelheim has announced that it will cap out-of-pocket costs for eligible patients at $35 per month for all of its inhaler products in the U.S.
2. This initiative will benefit uninsured and under-insured patients who rely on inhalers for asthma and COPD treatment.
3. The company will also lower the list price of some of its inhalers.
4. The decision comes after a Senate Health, Education, Labor, and Pensions (HELP) Committee investigation led by Sen. Bernie Sanders, which highlighted the high cost of inhalers in the U.S. compared to other countries.
5. The $35 cap will take effect on June 1, 2024.
6. Boehringer Ingelheim's Spiriva HandiHaler, for example, could potentially save a patient more than $3,000 a year with the new cap.
7. Sen. Sanders has called on other major inhaler manufacturers, such as AstraZeneca, GlaxoSmithKline, and Teva, to follow Boehringer Ingelheim's lead.

These developments aim to make inhalers more affordable for patients in the U.S., where costs have been significantly higher than in other parts of the world.